Comparison of Ticagrelor with Clopidogrel on Coronary Microvascular Dysfunction Following Acute Myocardial Infarction Using Angiography-Derived Index of Microcirculatory Resistance
Open Access
- 2 September 2024
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (5) , 1097-1111
Abstract
Purpose This research aimed to assess the impact of ticagrelor and clopidogrel on coronary microvascular dysfunction (CMD) and prognosis following acute myocardial infarction (AMI), using the angiography-derived index of microcirculatory resistance (angio-IMR) as a non-invasive assessment tool. Methods In this retrospective study, angio-IMR was performed to evaluate CMD before and after dual antiplatelet therapy (DAPT) with either ticagrelor (90 mg twice daily, n = 184) or clopidogrel (75 mg once daily, n = 72). The primary endpoint is the improvement of CMD evaluated by angio-IMR (delta angio-IMR) following DAPT. Secondary endpoints included myocardial reinfarction and readmission for heart failure during 2-year follow-up. Results Compared with clopidogrel, ticagrelor exhibited a significantly higher delta angio-IMR [− 3.09 (5.14) versus − 1.99 (1.91), P = 0.008], indicating a superior improvement of CMD with ticagrelor treatment. Multivariate Cox regression indicated that ticagrelor treatment was related to a reduced risk of readmission for heart failure [8 (4.3) versus 9 (12.5), adjusted HR = 0.329; 95% CI = 0.116–0.934; P = 0.018] and myocardial reinfarction [7 (3.8) versus 8 (11.1), adjusted HR = 0.349; 95% CI = 0.125–0.975; P = 0.026]. Furthermore, ticagrelor treatment serves as an independent predictor of readmission for heart failure (HR = 0.322; 95% CI = 0.110–0.943; P = 0.039). Conclusion The results of this study indicate a potential association between ticagrelor treatment and improved CMD, as well as a reduced risk of cardiovascular events, including myocardial reinfarction and readmission for heart failure in AMI patients. Further randomized controlled trials are necessary to confirm the potential benefits of ticagrelor on CMD and cardiovascular prognosis. This clinical trial was registered in www.clinicaltrials.gov (NCT05978726).Keywords
This publication has 30 references indexed in Scilit:
- Ischemia With Nonobstructive Coronary Artery DiseaseJACC: Asia, 2023
- A novel CFD-based computed index of microcirculatory resistance (IMR) derived from coronary angiography to assess coronary microcirculationComputer Methods and Programs in Biomedicine, 2022
- Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial InfarctionAdvances in Therapy, 2022
- Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection FractionJAMA Cardiology, 2021
- Angiography-derived index of microcirculatory resistance as a novel, pressure-wire-free tool to assess coronary microcirculation in ST elevation myocardial infarctionThe International Journal of Cardiovascular Imaging, 2020
- Endothelium-Dependent and Independent Coronary Microvascular Dysfunction in Patients with Heart Failure with Preserved Ejection FractionEuropean Journal of Heart Failure, 2019
- TicagrelorInterventional Cardiology Clinics, 2017
- Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary SyndromeJACC, 2014
- Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in HumansJACC, 2013
- Calculation of the Index of Microcirculatory Resistance Without Coronary Wedge Pressure Measurement in the Presence of Epicardial StenosisJACC: Cardiovascular Interventions, 2013